Concerta should not be used in patients being treated (currently or within the preceeding 2 weeks) with MAOIs (see Contraindications).
Because of possible increases on blood pressure, Concerta should be used cautiously with vasopressor agents.
Human pharmacologic studies have shown that methylphenidate may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (eg, phenobarbital, phenytoin, primidone) and some antidepressants (tricyclics and selective serotonin re-uptake inhibitors). Downward dose adjustment of these drugs may be required when given concomitantly with methylphenidate. It may be necessary to adjust the dosage and monitor plasma drug concentrations (or in the case of coumarin, coagulation times), when initiating or discontinuing concomitant methylphenidate.
Serious adverse events have been reported in concomitant use with clonidine, although no causality for the combination has been established. The safety of using methylphenidate in combination with clonidine or other centrally-acting α2-agonists has not been systematically evaluated.
Incompatibilities: None known.